Novavax, Inc. (NVAX)

Market Cap	1.17B
Revenue (ttm)	682.16M
Net Income (ttm)	-187.50M
Shares Out	160.84M
EPS (ttm)	-1.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,386,880
Open	7.36
Previous Close	7.39
Day's Range	7.24 - 7.42
52-Week Range	3.81 - 23.86
Beta	2.91
Analysts	Buy
Price Target	17.83 (+145.59%)
Earnings Date	May 9, 2025

About NVAX

Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adoles...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 5, 1995
• Employees: 952
• Stock Exchange: NASDAQ
• Ticker Symbol: NVAX
• Website: https://global.novavax.com

Financial Performance

In 2024, Novavax's revenue was $682.16 million, a decrease of -30.65% compared to the previous year's $983.71 million. Losses were -$187.50 million, -65.60% less than in 2023.

Analyst Forecast

According to 6 analysts, the average rating for NVAX stock is "Buy." The 12-month stock price forecast is $17.83, which is an increase of 145.59% from the latest price.

Price Target

$17.83

(145.59% upside)

Analyst Consensus: Buy